



## **PARALLEL SESSION 1.3**

SAFEGUARDING MEDICINES IN THE ERA OF AMR: WHAT DO WE KNOW? WHAT WORKS?





## | BACKGROUND

The prevention, detection and mitigation of emerging and re-emerging infectious diseases involve both applying preventive controls in animal production as well as ensuring the safety, efficacy, quality, and appropriate use of vaccines, diagnostics and medicines through secure supply chains and health delivery systems.


Complex and fragmented supply chains, especially in countries and regions with limited regulatory and quality oversight, increase the likelihood of substandard, fraudulent or adulterated medicines entering the market. Poor quality medicines ensure microbial replication in the presence of drug pressure. Substandard and falsified medicines also contribute to lack of efficacy and adverse events, undermining trust in the health system. Inappropriate use of anti-microbials is another driver of AMR. Both poor quality medicines and inappropriate use are preventable and can be addressed through the development of robust regulatory and quality assurance systems, treatment guidelines and enforcement.

While there are major limitations in evidence and best practice in the human health sector, even less is known in the veterinary sector, both with respect to use and quality of antibiotics in animals, and effective controls. Further, environmental factors are beginning to come to light.

## | OBJECTIVES

- Review evidence of what is known about the links between medicines quality and AMR.
- Highlight successful efforts in, and benefits from, strengthening systems that monitor and strive to improve medicines quality.
- Address environmental impacts of antibiotic manufacturing on AMR.
- Relate frameworks for addressing medicines quality and appropriate use in the human sector to the animal sector and discern what lessons and approaches from other initiatives could be mobilized to address these drivers of infectious disease risk and AMR.









## Panelist

Damiano de Felice

Director of Strategy

Access to Medicine Foundation Netherlands

Damiano de Felice is Director of Strategy and Member of the Management Team at the Access to Medicine Foundation. He leads the strategy of the organisation, focuses on enhancing its impact, manages the relationship with governments and investors, is responsible for fundraising and oversees finances. Damiano is an expert in the relationship between business, human rights and development, and a member of the World Economic Forum Global Future Council on Human Rights. Damiano holds a PhD in International Relations from the London School of Economics, and two Master's degrees in Political Science and International Relations (from the University of Pisa and the Sant'Anna School of Advanced Studies respectively). During his career, Damiano has advised international organizations, companies, governments and NGOs, and published several papers on human rights and development issues. To stimulate positive change within the pharmaceutical industry, Damiano often speaks publicly on access-to-medicine matters on platforms hosted by international, governmental and nongovernmental organizations, including the UN and WHO.